Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)

Key Inclusion Criteria:

• Diagnosed IgAN, with biopsy confirmation

• 24-hr proteinuria excretion ≥1.0 g/day or 24-hour uPCR ≥0.75 g/g

• Estimated glomerular filtration rate (eGFR) ≥ 30 mL/min/1.73m^2

• Stable angiotensin converting enzyme inhibitor (ACEi) or angiotensin II receptorblocker (ARBs) as per protocol specification

Key Exclusion Criteria:

• Have received any immunosuppressive treatment or procedures (includingcorticosteroids, oral immunosuppressive agents, B cell or plasma cell targetedtherapies, complement targeted therapies, herbal medicines per protocol, andtonsillectomy) within a wash-out period per protocol

• Rapidly progressive glomerulonephritis with eGFR reduction >50% within 12 weeks ofthe start of screening

Other protocol defined Inclusion/Exclusion criteria may apply.